Enzyme replacement in Anderson-Fabry disease [9]

Lancet

Volumn 361, Issue 9354, 2003, Pages 352-

  Bengtsson, Bengt Åke ^a   Johansson, Jan Ove ^a   Hollak, Carla ^b   Linthorst, Gabor ^b   FeldtRasmussen, Ulla ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; CERAMIDE DERIVATIVE; GLYCOSPHINGOLIPID; INULIN; PLACEBO; SPHINGOLIPID;

ANDERSON FABRY DISEASE; BRAIN DISEASE; CARDIOMYOPATHY; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOSE CALCULATION; DRUG APPROVAL; DRUG COST; DRUG EFFECT; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; EUROPE; FOOD AND DRUG ADMINISTRATION; GENETIC DISORDER; HUMAN; KIDNEY FAILURE; LETTER; PAIN; PRIORITY JOURNAL; UNITED STATES;

EID: 0037464734     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12357-4     Document Type: Letter

References (2)

1. Schiffman R., Kopp J.B., Austin H.A., et al. Enzyme replacement therapy in Fabry disease. A randomised controlled trial. JAMA. 285:2001;2743-2749.
2. Eng C., Guffon N., Wilcox W.R., et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 345:2001;9-16.